A child presented with obstructive sleep apnea (OSA) and a near-fatal airway obstruction and respiratory arrest shortly after receiving chloral hydrate (CH). We, therefore, hypothesize that CH might selectively depress upper airway maintaining muscles such as the genioglossus and so predispose to airway obstruction.
contrast, peak and phasic DIA I EMGs after CH were not significantly different from those before CH administration. We conclude that hypnotic doses of CH may preferentially depress GG activity as compared with DIA activity. Selective depression of airway-maintaining muscular contraction by CH may place susceptible patients at risk for life-threatening airway obstruction and may preclude the use of CH to facilitate sleep for polygraphic evaluations in patients suspected of having OSA. Abbreviations CH, chloral hydrate DIA, diaphragm GG, genioglossus I EMG, integrated electromyogram OSA, obstructive sleep apnea tcPo2, transcutaneous partial pressure of oxygen CH is a widely used hypnotic drug. Miller and Greenblatt (12) reported that 2 1 % of hospitalized medical patients received CH, and, in some hospitals, as many as one-third of patients receive CH (8) . One reason for this popularity is that, unlike barbiturates and other sedative-hypnotics, therapeutic doses of CH are not thought to diminish inspiratory drive. If true, this property of CH would greatly facilitate investigations of sleep-related breathing abnormalities in patients who have difficulty falling asleep spontaneously.
Recently, a child with OSA had a respiratory arrest shortly after CH administration. Observation just before the respiratory arrest suggested that the patient had upper airway obstruction. We therefore designed the present study to investigate whether CH selectively depresses upper airway-maintaining musculature and so might predispose to life-threatening OSA.
The GG was chosen for study because GG contraction, which pulls the tongue forward out of the pharyngeal airway, is thought to help maintain pharyngeal airway patency (13) . Recent studies have shown that other pharyngeal muscles besides the GG also are involved in the maintenance of upper airway patency (4, 7).
CASE REPORT
A 15-mo-old black male was referred for evaluation of recurrent pneumonia. Physical examination revealed a cachectic boy with moderately enlarged tonsils but no evidence of airway obstruction during wakefulness; however, examination during sleep revealed snoring and episodes of labored breathing without air movement, suggestive of OSA (4) . Cardiomegaly on chest xray and right ventricular hypertrophy on both electrocardiogram and echocardiogram indicated cor pulmonale (9) . Polygraphic monitoring revealed intermittent obstructive apnea during sleep associated with hypercarbia and severe hypoxia (tcP02 as low as 35 mm Hg). After diagnostic bronchoscopy under general anesthesia, the patient would not resume spontaneous breathing. A tracheostomy was then performed. Thereafter, the patient had no difficulties with breathing during sleep. Weight increased from the 5th to greater than the 95th percentile and, by age 28 mo, laboratory evidence of cor pulmonale disappeared.
To assess upper airway patency at age 3 yr, a small tracheostomy tube was plugged. The patient could breathe easily around the plug when awake, and, for the next 3 d the patient did well during natural sleep with only minimal retractions and no identifiable apneic spells. To further evaluate whether partial airway obstruction during sleep would cause difficulty if the tracheostomy tube was removed, polygraphic monitoring and upper airway fluoroscopy during an afternoon nap were planned. To facilitate sleep, the patient was given 55 mg/kg CH orally. Because the patient remained alert, a second dose of 55 mg/kg CH was given I h later. Within 15 min after the second CH dose, the bedside nurse witnessed a period of vigorous respiratory movements without airflow (obstructive apnea). The patient then stopped breathing, became bradycardic and required resuscitation and intermittent positive pressure ventilation. Subsequently, the patient was re-evaluated during a daytime nap without sedation. We found sleep-related tonsillar obstruction and, after tonsillectomy, tracheal decannulation was accomplished.
MATERIALS AND METHODS
Four New Zealand white rabbits and four cats were anesthetized by intraperitoneal injection of 25 mg/kg ketamine and 5 mg/kg of xylazine. Additional doses were given as needed. Two percent xylocaine was used for local anesthesia.
EMGs were recorded from fine wire electrodes (I) placed in a GG muscle and in the DIA as previously described (5, 6) . A nasogastric tube was inserted for CH administration. After insertion of the electrodes and nasogastric tube, the animals were allowed to recover from anesthesia for at least 2 h. Adequate recovery was judged to be present when the animal exhibited spontaneous body movements, sniffing and chewing, and responded to touch.
EMGs were amplified (Grass P15) 100-1000 times with 30 and 1000 Hz low and high frquency filters. Raw EMGs were rectified and electrically integrated with a RC circuit (Beckman 9852A). The integrator response time to a step increase in activity was 90% complete in 250 ms (6) . Raw and integrated EMGs were recorded on a polygraph for later analysis. During recordings each animal was tightly placed in a metal screened restraining cage to reduce background electrical noise and to maintain the animals as much as possible with the neck extended in the "snifing position."
After recovery from anesthesia, GG and DIA EMGs were recorded for 30 min before CH administration (control period). CH was then administered by nasogastric tube and recordings continued for at least 60 min by which time trichloroethanol, the active metabolite of CH, would have peaked (3) . Subsequent CH doses were administered in two animals in which the initial CH dose failed to induce sleep. For each animal, the first dose which induced sleep was chosen for analysis. Sleep was judged to be present when the animal was quiet without vigorous movements, had eyes closed, and exhibited little or no response to stimuli. The initial CH dose was 250 mg/kg in six animals, 125 mg/kg in one animal, and 1000 mg/kg in one animal. From previous work, 250 mg/kg was considered the smallest dose likely to induce sleep (2, 10) and this initial CH dose did indeed induce sleep in six animals. In one animal in which 125 mg/kg did not induce sleep, a subsequent dose of 200 mg/kg did; in one animal doses of 250 and 500 mg/kg failed to induce sleep but a subsequent dose of 1000 mg/kg did.
Data analysis. Integrated GG and DIA EMGs were analyzed at 10-min intervals from 30 min before until 60 min after CH administration. Peak (inspiratory) I EMGs and minimum (expiratory) I EMGs were measured from six consecutive breaths at each time. The phasic change in I EMGs was calculated as the difference between peak I EMG and minimum I EMG for each muscle. Peak, minimum, and phasic values from the six individual breaths at each time were averaged. The average peak activity in the control period was obtained by averaging the values for peak I GG EMG and peak I DIA EMG in the control period. Values for peak, minimum, and phasic I EMG for each muscle and at each time were then expressed as a percentage of average peak I EMG in the control period. Graphs were constructed to show the values of peak, minimum, and phasic I EMGs for individual animals against time.
Data from individual animals were averaged to obtain group means. Because results from rabbits and cats were similar, data from the two species were pooled. To demonstrate the differential effect of CH on GG EMG, peak I GG EMG was divided by peak I DIA EMG at each time, and then expressed as a percentage of the average ratio in the control period. The ratio of peak I G G EMG to peak I DIA EMG was displayed graphically both for individual animals and for the group mean. Statistical significance of results was assessed by the two-tailed paired t test comparing peak, minimum and phasic values for I GG EMG and for I DIA EMG at each time to corresponding values in the control period. All values are shown as mean k SD.
RESULTS
The dose of CH required to induce sleep was 250 mg/kg in five animals, 200 mg/kg in one animal, and 1000 mg/kg in the other two animals. Peak I GG EMG decreased within 10-20 min after the hypnotic dose of CH in seven of eight animals. By contrast, no consistent effect on peak I DIA EMG was seen. As shown in Figure 1 , the decrease in peak GG EMG activity was due in part to a depression of tonic (minimum expiratory) I GG EMG activity and, in part, to a depression of the phasic inspiratory increase in I GG EMG. Figures 2A and B EMGs, respectively, for a single animal from 30 min before to Peak I DIA EMGs for individual animals increased in two, decreased in three, and did not change in three.
* All values are expressed as a percentage of the average peak integrated ~i~~~~~ 5~ and B show values for the ratio of peak I GG EMG EMG for that muscle in the control period: .f + SD are shown.
to peak I DIA EMG for individual animals and for group mean t Peak, minimum, and phasic integrated EMGS at each time are data, respectively. A decrease in this ratio expresses a differential compared with their respective values in the control period using the depressant effect of CH upon GG with DIA two-tailed, paned t test; * P < 0.05; **P < 0.01; and ***P < 0.001.
activity. The ratio of peak I G G EMG to peak I DIA EMG decreased in seven of eight animals and was virtually unchanged in the one animal in which both EMGs increased. Group mean data for the ratio of peak I G G EMG to peak I DIA EMG
PERK GENIOGLOSSUS EMG FOR INDIVIDURL RNIMRLS
decreased to as low as 30.0 a 17.7% of the pre-CH ratio. 
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DISCUSSION
The results of this study demonstrate that in both cats and rabbits, hypnotic doses of CH selectively depress activity of the G G muscle compared with the DIA. The CH-induced G G depression was noticeable throughout the respiratory cycle with significant decreases in peak, minimum, and phasic I G G EMGs.
Depression of G G activity began within 10-20 min after CH administration and lasted several hours. This time course of G G depression is consistent with the known time course of blood levels of trichloroethanol, the active metabolite of CH (3).
Previous studies have investigated the effects of CH on breathing but not explored the effects of CH on upper ainvay-maintaining musculature. Lees et al. (1 1) found no changes in baseline respiratory parameters or in hypercarbic ventilatory responses in tracheostomized puppies after 100 mg/kg of CH or in infants after 50 mg/kg of CH. Likewise, Hunt et al. (10) found no significant differences in baseline respiratory parameters or in hypercarbic or hypoxic ventilatory responses after 250 mg/kg of CH in tracheostomized rabbits (10) . These studies suggested that, in patients who did not have a propensity towards airway obstruction, CH may be used for studies of sleep-related breathing control.
The finding that CH depresses G G but not DIA activity and the case report of a near-fatal airway obstruction after CH administration suggest that CH may depress G G and other airway-maintaining muscles in patients at risk for life-threatening airway obstruction including those with OSA. Such depression of upper airway-maintaining muscular activity could increase the frequency and/or duration of OSA episodes. Besides the immediate dangers of asphyxia1 brain damage and death, this effect could confound polygraphic evaluations of breathing in OSA patients. We, therefore, recommend that CH not be given to patients suspected of having OSA and that studies of sleeprelated breathing control be performed only during nocturnal sleep or daytime naps (4).
